Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease

Abstract Recently, there has been an increasing interest in the therapeutic efficacy of RAS inhibitors (RASi) in patients with non-alcoholic fatty liver disease (NAFLD) because they may reduce oxidative stress, inflammatory markers, and enhanced fibrosis. An objective of this study was to investigat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kwang Min Kim, Ji-Hye Roh, Sangjin Lee, Jeong-Hyun Yoon
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/648294fd0b844a61a38cb4f6b5afa69b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:648294fd0b844a61a38cb4f6b5afa69b
record_format	dspace
spelling	oai:doaj.org-article:648294fd0b844a61a38cb4f6b5afa69b2021-12-02T14:06:56ZClinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease10.1038/s41598-021-81959-12045-2322https://doaj.org/article/648294fd0b844a61a38cb4f6b5afa69b2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81959-1https://doaj.org/toc/2045-2322Abstract Recently, there has been an increasing interest in the therapeutic efficacy of RAS inhibitors (RASi) in patients with non-alcoholic fatty liver disease (NAFLD) because they may reduce oxidative stress, inflammatory markers, and enhanced fibrosis. An objective of this study was to investigate the role of RASi on NAFLD development and progression in a large cohort. We conducted a nested case–control study. Study subjects were classified into two study cohorts according to baseline NAFLD status: non-NAFLD (n = 184,581) and established NALFD (n = 27,565). An NAFLD development or progression case was defined as a patient with newly developed NAFLD or new progression of advanced fibrosis from non-NAFLD and established NALFD cohorts, respectively. A conditional logistic regression analysis was conducted to estimate the associations between RASi exposure and NAFLD development/progression. Overall, no significant association was evident between RASi use and NAFLD development or progression (NAFLD development; ever-user vs. never-user: OR 1.017; 95% CI 0.842–1.230, NAFLD progression; ever-user vs. never-user: aOR 0.942; 95% CI 0.803–1.105). RASi ever-use in cases of individuals who were obese or who had normal fasting plasma glucose (FPG) was associated with reduced risk of both NAFLD development (body mass index (BMI) ≥ 25 kg/m2: 0.708 [95% confidence interval (CI) 0.535–0.937], FPG of < 100 mg/mL: 0.774 [95% CI 0.606–0.987]) and progression (BMI ≥ 25 kg/m2: 0.668 [95% CI 0.568–0.784], FPG of < 100 mg/mL: 0.732 [95% CI 0.582–0.921]). The present study did not verify a significant overall association between RASi use and NAFLD development/progression but suggested that RASi might prevent NAFLD development and progression among specific subjects.Kwang Min KimJi-Hye RohSangjin LeeJeong-Hyun YoonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kwang Min Kim Ji-Hye Roh Sangjin Lee Jeong-Hyun Yoon Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
description	Abstract Recently, there has been an increasing interest in the therapeutic efficacy of RAS inhibitors (RASi) in patients with non-alcoholic fatty liver disease (NAFLD) because they may reduce oxidative stress, inflammatory markers, and enhanced fibrosis. An objective of this study was to investigate the role of RASi on NAFLD development and progression in a large cohort. We conducted a nested case–control study. Study subjects were classified into two study cohorts according to baseline NAFLD status: non-NAFLD (n = 184,581) and established NALFD (n = 27,565). An NAFLD development or progression case was defined as a patient with newly developed NAFLD or new progression of advanced fibrosis from non-NAFLD and established NALFD cohorts, respectively. A conditional logistic regression analysis was conducted to estimate the associations between RASi exposure and NAFLD development/progression. Overall, no significant association was evident between RASi use and NAFLD development or progression (NAFLD development; ever-user vs. never-user: OR 1.017; 95% CI 0.842–1.230, NAFLD progression; ever-user vs. never-user: aOR 0.942; 95% CI 0.803–1.105). RASi ever-use in cases of individuals who were obese or who had normal fasting plasma glucose (FPG) was associated with reduced risk of both NAFLD development (body mass index (BMI) ≥ 25 kg/m2: 0.708 [95% confidence interval (CI) 0.535–0.937], FPG of < 100 mg/mL: 0.774 [95% CI 0.606–0.987]) and progression (BMI ≥ 25 kg/m2: 0.668 [95% CI 0.568–0.784], FPG of < 100 mg/mL: 0.732 [95% CI 0.582–0.921]). The present study did not verify a significant overall association between RASi use and NAFLD development/progression but suggested that RASi might prevent NAFLD development and progression among specific subjects.
format	article
author	Kwang Min Kim Ji-Hye Roh Sangjin Lee Jeong-Hyun Yoon
author_facet	Kwang Min Kim Ji-Hye Roh Sangjin Lee Jeong-Hyun Yoon
author_sort	Kwang Min Kim
title	Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
title_short	Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
title_full	Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
title_fullStr	Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
title_full_unstemmed	Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
title_sort	clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/648294fd0b844a61a38cb4f6b5afa69b
work_keys_str_mv	AT kwangminkim clinicalimplicationsofreninangiotensinsysteminhibitorsfordevelopmentandprogressionofnonalcoholicfattyliverdisease AT jihyeroh clinicalimplicationsofreninangiotensinsysteminhibitorsfordevelopmentandprogressionofnonalcoholicfattyliverdisease AT sangjinlee clinicalimplicationsofreninangiotensinsysteminhibitorsfordevelopmentandprogressionofnonalcoholicfattyliverdisease AT jeonghyunyoon clinicalimplicationsofreninangiotensinsysteminhibitorsfordevelopmentandprogressionofnonalcoholicfattyliverdisease
_version_	1718391966467620864

Clinical implications of renin–angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease

Ejemplares similares